EP1121435A1 - Camel, an alternative translation product of the tumour antigen lage-1 - Google Patents
Camel, an alternative translation product of the tumour antigen lage-1Info
- Publication number
- EP1121435A1 EP1121435A1 EP99953854A EP99953854A EP1121435A1 EP 1121435 A1 EP1121435 A1 EP 1121435A1 EP 99953854 A EP99953854 A EP 99953854A EP 99953854 A EP99953854 A EP 99953854A EP 1121435 A1 EP1121435 A1 EP 1121435A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- camel
- tumor
- lage
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 49
- 108091007433 antigens Proteins 0.000 title claims abstract description 40
- 102000036639 antigens Human genes 0.000 title claims abstract description 40
- 239000000427 antigen Substances 0.000 title claims abstract description 39
- 241000282836 Camelus dromedarius Species 0.000 title claims abstract 4
- 238000013519 translation Methods 0.000 title description 12
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 claims abstract description 136
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 claims abstract description 135
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 122
- 230000002163 immunogen Effects 0.000 claims abstract description 21
- 108020004414 DNA Proteins 0.000 claims abstract description 10
- 238000002619 cancer immunotherapy Methods 0.000 claims abstract description 5
- 239000002299 complementary DNA Substances 0.000 claims description 59
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 102000053602 DNA Human genes 0.000 claims description 8
- 101000666833 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.8 kDa protein in FGF-VUBI intergenic region Proteins 0.000 claims description 7
- 101000977027 Azospirillum brasilense Uncharacterized protein in nodG 5'region Proteins 0.000 claims description 7
- 101000933555 Bacillus subtilis (strain 168) Biofilm-surface layer protein A Proteins 0.000 claims description 7
- 101000962005 Bacillus thuringiensis Uncharacterized 23.6 kDa protein Proteins 0.000 claims description 7
- 101000785191 Drosophila melanogaster Uncharacterized 50 kDa protein in type I retrotransposable element R1DM Proteins 0.000 claims description 7
- 101000747704 Enterobacteria phage N4 Uncharacterized protein Gp1 Proteins 0.000 claims description 7
- 101000861206 Enterococcus faecalis (strain ATCC 700802 / V583) Uncharacterized protein EF_A0048 Proteins 0.000 claims description 7
- 101000769180 Escherichia coli Uncharacterized 11.1 kDa protein Proteins 0.000 claims description 7
- 101000976301 Leptospira interrogans Uncharacterized 35 kDa protein in sph 3'region Proteins 0.000 claims description 7
- 101000658690 Neisseria meningitidis serogroup B Transposase for insertion sequence element IS1106 Proteins 0.000 claims description 7
- 101000748660 Pseudomonas savastanoi Uncharacterized 21 kDa protein in iaaL 5'region Proteins 0.000 claims description 7
- 101000584469 Rice tungro bacilliform virus (isolate Philippines) Protein P1 Proteins 0.000 claims description 7
- 101000773449 Sinorhizobium fredii (strain NBRC 101917 / NGR234) Uncharacterized HTH-type transcriptional regulator y4sM Proteins 0.000 claims description 7
- 101000818096 Spirochaeta aurantia Uncharacterized 15.5 kDa protein in trpE 3'region Proteins 0.000 claims description 7
- 101000766081 Streptomyces ambofaciens Uncharacterized HTH-type transcriptional regulator in unstable DNA locus Proteins 0.000 claims description 7
- 101000987243 Streptomyces griseus Probable cadicidin biosynthesis thioesterase Proteins 0.000 claims description 7
- 101000804403 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HIT-like protein Synpcc7942_1390 Proteins 0.000 claims description 7
- 101000750910 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HTH-type transcriptional regulator Synpcc7942_2319 Proteins 0.000 claims description 7
- 101000644897 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) Uncharacterized protein SYNPCC7002_B0001 Proteins 0.000 claims description 7
- 101000916336 Xenopus laevis Transposon TX1 uncharacterized 82 kDa protein Proteins 0.000 claims description 7
- 101001000760 Zea mays Putative Pol polyprotein from transposon element Bs1 Proteins 0.000 claims description 7
- 101000678262 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 65 kDa protein Proteins 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000011275 oncology therapy Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- ZBLQIYPCUWZSRZ-QEJZJMRPSA-N Ala-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 ZBLQIYPCUWZSRZ-QEJZJMRPSA-N 0.000 claims 2
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 claims 2
- WOMUDRVDJMHTCV-DCAQKATOSA-N Glu-Arg-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WOMUDRVDJMHTCV-DCAQKATOSA-N 0.000 claims 2
- 108010076756 leucyl-alanyl-phenylalanine Proteins 0.000 claims 2
- XSTZMVAYYCJTNR-DCAQKATOSA-N Ala-Met-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O XSTZMVAYYCJTNR-DCAQKATOSA-N 0.000 claims 1
- PHONXOACARQMPM-BQBZGAKWSA-N Gly-Ala-Met Chemical compound [H]NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(O)=O PHONXOACARQMPM-BQBZGAKWSA-N 0.000 claims 1
- CPONGMJGVIAWEH-DCAQKATOSA-N Leu-Met-Ala Chemical compound CSCC[C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](C)C(O)=O CPONGMJGVIAWEH-DCAQKATOSA-N 0.000 claims 1
- AFFKUNVPPLQUGA-DCAQKATOSA-N Met-Leu-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O AFFKUNVPPLQUGA-DCAQKATOSA-N 0.000 claims 1
- LBNFTWKGISQVEE-AVGNSLFASA-N Met-Leu-Met Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCSC LBNFTWKGISQVEE-AVGNSLFASA-N 0.000 claims 1
- KPEIBEPEUAZWNS-ULQDDVLXSA-N Phe-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 KPEIBEPEUAZWNS-ULQDDVLXSA-N 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 63
- 108700026244 Open Reading Frames Proteins 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 56
- 108090000623 proteins and genes Proteins 0.000 description 35
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 33
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 26
- 201000001441 melanoma Diseases 0.000 description 26
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 21
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 21
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 101100326920 Caenorhabditis elegans ctl-1 gene Proteins 0.000 description 17
- 238000003556 assay Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 13
- 230000014616 translation Effects 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 102000011786 HLA-A Antigens Human genes 0.000 description 10
- 108010075704 HLA-A Antigens Proteins 0.000 description 10
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 9
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000005847 immunogenicity Effects 0.000 description 8
- 238000000636 Northern blotting Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 4
- 101710102803 Tumor suppressor ARF Proteins 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 230000014621 translational initiation Effects 0.000 description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108091006054 His-tagged proteins Proteins 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 description 2
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 description 2
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 description 2
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 description 2
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 description 2
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 description 2
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 2
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 description 2
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 description 2
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 description 2
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 description 2
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 description 2
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 description 2
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 description 2
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 description 2
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 description 2
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 description 2
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 description 2
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 description 2
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 description 2
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 description 2
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 description 2
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 description 2
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 description 2
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 description 2
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 description 2
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 2
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 2
- 102100024407 Jouberin Human genes 0.000 description 2
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 description 2
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 description 2
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 description 2
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 description 2
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 description 2
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 description 2
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 description 2
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 description 2
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 description 2
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 description 2
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 description 2
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 description 2
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 description 2
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 description 2
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 description 2
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 description 2
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 description 2
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 238000001400 expression cloning Methods 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- PQGCYSRGXCORLN-UHFFFAOYSA-N 2-[[2-[2-[[2-[[1-[2-[[2-[[2-[(2-amino-3-phenylpropanoyl)amino]-4-methylpentanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoylamino]-4-methylpentanoyl]amino]-3-methylbutan Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NCC(=O)N1C(CCC1)C(=O)NC(CCCN=C(N)N)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(N)CC1=CC=CC=C1 PQGCYSRGXCORLN-UHFFFAOYSA-N 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 102100031699 Choline transporter-like protein 1 Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241001146209 Curio rowleyanus Species 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 1
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000940912 Homo sapiens Choline transporter-like protein 1 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003127 anti-melanomic effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to the field of cancer therapy, more specifically to tumor-associated antigens.
- Cytotoxic T lymphocytes play an important role in the defense against melanoma.
- Melanoma-specific CTL clones have been obtained from either tumor infiltrating lymphocytes (TIL) in vitro stimulated with cytokines, or from peripheral blood mononuclear cells (PBMC) cultured with (autologous) tumor cells. T cell responses against tumor cells are enhanced by cytokine transfection of the tumor cells, both in animal models and in in vitro human culture systems, (van Elsas et al., 1997; Gansbacher et al., 1990; Tepper et al., 1989; Fearon et al., 1990; Dranoff et al., 1993)
- T cell targets can be divided in three groups: 1) tumor-specific antigens, not expressed in healthy tissues, except testis and placenta (e.g., MAGE, BAGE, GAGE, NY-ESO-1 , LAGE-1); 2) antigens that are lineage-specific and expressed in both melanoma and melanocytes (e.g., MART-1/ Melan- A, gp100, tyrosinase) and 3) unique, mutated antigens (e.g., ⁇ -catenin, CDK4, MUM-1) (reviewed by Van den Eynde and Brichard, 1995).
- testis and placenta e.g., MAGE, BAGE, GAGE, NY-ESO-1 , LAGE-1
- antigens that are lineage-specific and expressed in both melanoma and melanocytes e.g., MART-1/ Melan- A, gp100, tyrosinase
- RDA Representational Difference Analysis
- NY-ESO-1 is a gene originally identified by SEREX technology (Chen et al., 1997). It was shown to have two different reading frames (DNA sequences and derived protein sequences given in SEQ ID NO: 7 - 10), translation products of which were shown to contain epitopes of tumor specific T-cells (Jager et al., 1998; Wang et al., 1998).
- melanoma cell line 518A2 and its IL-2- or GM-CSF-transfectants were compared for their CTL stimulating capacity in vitro. Stimulation of autologous PBMC with the IL-2 producing melanoma cells resulted in a melanoma-specific CTL response (van Elsas et al., 1997).
- CTL clones derived from this culture recognized, besides autologous melanoma cell lines, also a panel of HLA-A * 0201 positive melanoma cell lines, but were not reactive with normal melanocytes.
- 518A2 was shown to express a number of antigens previously identified to be recognized by anti-melanoma CTL (van Elsas et al., 1996), the CTL clones available recognize a new melanoma-specific antigen that is immunodominant in 518A2.
- CAMEL CTL-recognized Antigen on Melanoma
- CAMEL is encoded by a reading frame of the LAGE-1 s -cDNA (SEQ ID NO:3) that is distinct from that encoding the putative LAGE-1 protein (SEQ ID NO: 4). (This reading frame is designated ORF-1.)
- a cDNA clone was identified that lacks the first 84 bp of the LAGE-1 3 sequence (SEQ ID NO: 3) which means that it is devoid of the initiation codon at position 54 of that sequence (Fig. 2a).
- the first possible translation initiation site in this clone (4H8) is the ATG at position 94 of LAGE-1 s (SEQ ID NO: 3), which is however, not in frame with the first ATG at position 54. Therefore, the CAMEL protein (SEQ ID NO: 2) translated from the 4H8 cDNA clone is different from the putative LAGE-1 s protein (SEQ ID NO: 4).
- the present invention is directed to the tumor-associated antigen CAMEL (SEQ ID NO: 2) which is encoded by an isolated DNA molecule with the sequence as defined in SEQ ID NO: 1.
- the coding sequence of CAMEL corresponds to the ORF-1 of LAGE-1 cDNA (Lethe et al., 1997; WO 98/32855).
- the present invention relates to immunogenic (poly)peptides derived from CAMEL.
- a first group of peptides is selected from peptides inducing a humoral immune response (induction of antibodies). Such peptides are selected by randomly choosing continuous stretches of amino acids (at least 12-15), applying them to an individual and confirming the generation of antibodies by standard immunological assays, e.g. ELISA.
- This group of immunogenic (poly)peptides also encompasses the entire CAMEL antigen or larger fragments thereof.
- the second group of peptides which is preferred, can be presented by MHC molecules (in humans: HLA molecules), they have the potential to induce an immune response, in particular by eliciting a CTL response.
- immunogenic peptides which have the ability to elicit a CTL response are selected from peptides with the sequence set forth in SEQ ID NO: 11 , 12, 24, 25 and 26.
- SEQ ID NO: 11 , 12, 24, 25 and 26 the selection of peptide sequences from a given antigen is, in the first place, based on the requirement for such peptide to bind to an MHC molecule present in the repertoire of the patient to be treated.
- Two classes of MHC molecules are distinguished, class I and class II.
- Class I molecules consist of a membrane-inserted heavy chain and a non-covalently attached light chain. In their structure, MHC class I molecules resemble a moose's head, the antlers forming a groove which is recognized by the peptide.
- HLA-A, B and C are the "classical" MHC class I molecules.
- Additional immunogenic peptides may be identified by methods known in the art which rely on the correlation between MHC-binding and CTL induction, e.g. those used by Stauss et al., 1992, who identified candidate T-cell epitopes in human papilloma virus.
- immunogenic peptides can be predicted based on their "peptide binding motif" synthetic peptides which represent CTL epitopes may be designed and synthesized.
- synthetic peptides which represent CTL epitopes may be designed and synthesized.
- the protein sequence is screened for stretches fitting to the basic anchor motif (two anchors in most cases), whereby allowance should be made for some variation in peptide lengths as well as in anchor occupancy. If a motif, for example calls for 9mers with lie or Leu at the end, 10mers with a fitting C-terminus should be considered as well, and other aliphatic residues at the C-terminus, like Val or Met, should also be considered. In this way, a list of peptide candidates is obtained.
- Binding assays can be performed at this stage to exclude weak binders which occur frequently among peptides conforming to a basic motif. If a detailed study on peptide binding requirements is available, the candidates can also be screened for non-anchor residues detrimental or optimal for binding (Ruppert et al., 1993).
- Examples for peptide candidates with potential immunogenicity that can be derived from the tumor-associated antigen of the present invention are the CAMEL-derived peptides with the sequence HLSPDQGRF and LMAQEALAF for HLA-A3 or RMAVPLLR ⁇ for HLA-A3101. Similarly, other peptides for these or for other alleles can be determined by the method mentioned above. The peptide binding can be tested in peptide binding assays.
- immunogenicity of the selected peptide or peptide equivalent as defined below, which is the crucial parameter for peptide-based vaccine development and which in most cases strongly correlates with the stability of the peptide-MHC interaction (van der Burg et al., 1996)
- the methods described by Sette et al., 1994, in combination with quantitative HLA-binding assays may be used.
- immunogenicity of the selected peptide may be checked by performing in vitro CTL induction by known methods e.g. as described below for ex vivo CTL induction.
- peptides derived from the naturally expressed tumor antigens functional equivalents thereof, i.e. peptides with partially altered sequences or substances mimicking peptides, e.g. "peptidomimetics” or retro-inverso peptides, may be obtained by the following methods:
- amino acid substitutions may be introduced at anchor positions to increase peptide MHC class I- binding affinity.
- the modified peptides are subsequently evaluated for enhanced binding and immunogenicity by screening for recognition by TIL (tumor-infiltrating lymphocytes) and CTL induction as described by Parkhurst at al, 1996, and Bakker et al., 1997.
- the selection of peptides capable of eliciting a cellular immune response is carried out in several steps, as described in WO 97/30721 , which disclosure is incorporated herein by reference.
- the candidates are first tested for their binding ability to an MHC molecule; subsequently good binders are tested for immunogenicity.
- a general strategy for obtaining efficient immunogenic peptides has been described by Schweighoffer, 1997.
- polypeptide of the present invention or immunogenic peptides derived from its sequence, respectively can be produced recombinantly or by peptide synthesis, as described in WO 96/10413, the disclosure of which is incorporated herein by reference.
- a DNA molecule encoding the antigen or the CTL peptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell, cultivated under conditions suitable for expression, recovered and purified.
- various conventional techniques may be used, e.g. commercially available automatic synthesizers.
- the tumor antigen of the present invention and the immunogenic peptides derived therefrom or the respective peptide equivalents are useful in cancer therapy, e.g. to induce, in the context of the appropriate MHC presenting molecule, an immunological response to tumors which express the corresponding antigen determinants.
- the induction of CTLs can be accomplished in vivo or ex vivo.
- a pharmaceutical composition comprising the peptide/antigen is administered to an individual suffering from a tumor associated with the respective tumor antigen in an amount sufficient to elicit an effective CTL response to the antigen-bearing tumor.
- the present invention provides pharmaceutical compositions for therapeutic treatment which are intended for parenteral, topical, oral or local administration.
- the compositions are for parenteral administration, e.g. for intravenous, subcutaneous, intradermal or intramuscular application.
- the peptides/antigens are dissolved or suspended in a pharmaceutically acceptable carrier, preferably an aqueous carrier.
- the composition may contain additional auxiliary substances, e.g. buffering agents, etc.
- the peptides may be used alone or in combination with adjuvants, e.g. saponins, alumn, or, in a particularly preferred embodiment, polycations, like polyarginine or polylysine.
- the peptides may also be linked to components assisting CTL priming, e.g. T helper peptides, lipids or liposomes or coadministered with such components or with immunostimulating substances, e.g. cytokines (IL-2, IFN- ⁇ ).
- cytokines IL-2, IFN- ⁇
- the immunogenic peptides may also be used to elicit a CTL response ex vivo.
- An ex vivo CTL response to a tumor expressing the antigen is induced by incubating a patient's CTL precursor cells together with antigen presenting cells and the immunogenic peptide.
- the thus activated CTLs are allowed to mature and expand to effector CTLs which are then readministered to the patient.
- the tumor antigen may be pulsed onto APCs which present MHC class ll-reactive peptides
- the peptides of the invention are preferably applied as a combination of peptides, e.g. different CAMEL-peptides.
- the peptides of the invention are combined with peptides derived from other tumor antigens, e.g. LAGE-1 and ESO-NY-1.
- the selection of the peptides is optimized towards covering multiple HLA types in order to be useful for a broad population of patients and/or towards a broad variety of malignancies, which is taken into account by combining peptides from a large variety of tumor antigens.
- the number of peptides suitable to be combined to yield an efficient therapy may vary within a broad range, e.g. from about 2 to approximately 100.
- the present invention is directed to an isolated DNA molecule with the sequence set forth in SEQ ID NO: 1 encoding CAMEL.
- This DNA molecule which is designated "CAMEL-DNA”
- contains the ORF-1 of LAGE-1 cDNA which is defined by nucleotides 54 - 336 of the sequence set forth in SEQ ID NO: 3.
- the CAMEL-DNA of the present invention may be used, as an alternative to the use of the protein or the peptide, for cancer immunotherapy.
- engineered derivatives may be utilized. These include sequences modified to encode (poly)peptides with improved immunogenicity, e.g. taking into account the modifications described above for the peptides. Another form of modification is the assembly of multiple sequences encoding immunologically relevant peptides in a so-called string-of-beads fashion, as described by Toes et al., 1997.
- the sequences may also be modified by adding auxiliary coding elements, e.g. targeting functions that ensure more efficient delivery and processing of the immunogen (e.g. Wu et al., 1995).
- the nucleic acid molecules may be delivered either directly or as part of a recombinant virus or bacterium.
- any method that is known for gene therapy may be applied for nucleic acid-based cancer immunotherapy, both in vivo and ex vivo.
- Examples for in vivo delivery are direct injection (injection of "naked” DNA) either intramuscularly or by "gene gun", which has been shown to result in the generation of CTLs against tumor antigens.
- Examples for recombinant organisms are vaccinia virus, fowlpox virus and adenovirus or Listeria monocytogenes (see Coulie, 1997 for a comprehensive review).
- synthetic nucleic acid carriers like cationic lipids, microspheres, microbeads, liposomes may be useful for in vivo delivery of the sequence encoding respective antigen/peptide.
- various auxiliary agents that enhance the immune response may be co-applied, e.g.
- cytokines either as proteins or as plasmids encoding these.
- Examples for ex vivo delivery are transfection of dendritic cells (Tuting, T., 1997) or other antigen presenting cells which are applied as a cellular cancer vaccine.
- the present invention is also directed to the use of cells that express the tumor-associated antigen of the invention, either naturally or upon transfection with the respective coding sequence, for the preparation of a tumor vaccine.
- NY-ESO-1 is a recently described tumor antigen, identified by screening a cDNA library of an esophagus carcinoma with autologous patient serum (SEREX-method (Chen et al., 1997)). NY-ESO-1 is expressed in different tumor types but not in healthy tissues except the testis.
- the epitope of specific CTL 1/29 was determined by cDNA expression cloning and a truncated LAGE-1 cDNA clone was found. This truncation led to the identification of the peptide epitope in an alternative reading frame, since the "normal" translation initiation site of LAGE-1 was absent.
- COS/HLA-A*0201 cells transfected with full length LAGE-1 or NY-ESO-1 cDNA clones could stimulate the CTL clone to TNF- production as well. This probably means that two different proteins can be translated from one single mRNA.
- NY-ESO-1 also has been described as the target of melanoma-specific HLA-A*0201 restricted CTL clones, which recognize an epitope translated in ORF3, located between aa 155 and 167 (Jager et al., 1998). Therefore, it is very likely that also LAGE-1 s will be recognized by these clones, but not LAGE-1 L , since the protein sequence is different at this part of the molecule.
- the CAMEL-specific CTL clones recognize a peptide in an alternative reading frame, which is encoded in both LAGE-1 and NY-ESO- 1. This means that tumor cells expressing either LAGE-1 or NY-ESO-1 can be recognized by MLMAQEALAFL-specific CTL, which might enlarge the number of tumors that can be treated with immunotherapy based on this peptide.
- FIG. 1 COS-7 transfection experiments with cDNA clone CAMEL and deletion constructs
- COS-7 cells were transfected with cDNAs as indicated and tested with CTL 1/29 in a TNF- ⁇ release assay.
- TNF- ⁇ release assay with predicted HLA-A * 0201 binding CAMEL peptides. Peptides as indicated were loaded on BLM, an HLA-A*0201 + melanoma cell line, at a concentration of 10 ⁇ g/ml and tested with CTL 1/29 in a TNF- ⁇ release assay.
- COS/HLA-A*0201 cells were transfected with these cDNA clones and reactivity with CTL 1/29 was measured in a TNF- ⁇ release assay.
- Figure 5 His-tagged CAMEL protein, synthesized in E.coli
- SEQ ID NO: 1 CAMEL (4H8) cDNA sequence and translation
- SEQ ID NO: 2 CAMEL protein sequence
- SEQ ID NO: 3 LAGE-1 s cDNA sequence and translation
- SEQ ID NO: 4 LAGE-1 s protein sequence
- SEQ ID NO: 5 LAGE-1 L cDNA sequence and translation
- SEQ ID NO: 6 LAGE-1 L protein sequence
- SEQ ID NO: 7 NY-ESO-1 cDNA sequence
- translation SEQ ID NO: 8 NY-ESO-1 protein sequence
- SEQ ID NO: 9 NY-ESO-1 cDNA and alternative translation
- SEQ ID NO: 10 protein sequence of alternatively translated NY-ESO-1
- SEQ ID NO: 11 peptide sequence of the CAMEL CTL epitope (11 -mer)
- SEQ ID NO: 12 peptide sequence of the CAMEL CTL epitope (10-mer)
- SEQ ID NO: 13 oligonucleotide SP6F-pSV
- SEQ ID NO: 14 oligonucleotide R1
- SEQ ID NO: 15 oligonucleotide R2
- SEQ ID NO: 16 oligonucleotide T7R-pSV
- SEQ ID NO: 17 oligonucleotide F3
- SEQ ID NO: 18 oligonucleotide ESO-1 B
- SEQ ID NO: 19 oligonucleotide ESO-1A
- SEQ ID NO: 20 oligonucleotide 4H8-A
- SEQ ID NO: 21 oligonucleotide 4H8-C
- Melanoma cell lines and COS-7 cells were maintained in DMEM containing 4.5 mM glucose supplemented with 8% FCS, 2 mM L-glutamine, 100 ⁇ g/ml of each penicillin and streptomycin.
- Melanoma cell line 518A2 was established from the dissected metastasis of a male patient in 1985, as described before (Versteeg et al., 1988).
- An IL-2 producing variant, 518/IL- 2.14, was obtained by transfection of 518A2 with the IL-2 cDNA (Osanto et al., 1993).
- melanoma cells that were used as targets in TNF- ⁇ release assay are FM3.29, FM6, FM28.4 and FM55P (gifts from J. Zeuthen, Denmark), MM127, MM415, MM485 (gifts from N. Hayward, Australia), SK- MEL-23, SK-MEL-29 (obtained from T. Wolfel, Mainz), MM0221 , Mi3046/2, NA8, BLM (obtained from M. Visseren, Leiden). EBV-transformed B-LCL and the TNF- ⁇ -sensitive WEHI-164 clone 13 (a gift from Dr. P. Coulie, Brussels) were cultured in RPMI-1640, supplemented with L-glutamine and antibiotics as above, and 10% FCS.
- a cDNA library of 518/IL-2.14 was constructed in the expression vector pSVsportl (GIBCO, BRL) using the Superscript Plasmid System (GIBCO, BRL).
- poly-A + mRNA was isolated using the Fast-Track system (Invitrogen), followed by reverse-transcription with an oligo-dT/Notl primer.
- Sail adapters were ligated to ds-cDNA and after Notl digestion and size fractionation, cDNA fragments were cloned into the pSVsportl vector digested with Sail and Notl.
- ElectroMAX-DH10B GIBCO, BRL
- 50-100 colonies were pooled for mini DNA isolation (QIAprep 8 plasmid kit, Qiagen).
- the in this way obtained cDNA pools were transfected in duplicate into COS-7 cells, together with the restriction element HLA-A * 0201 (pBJ1.neo/HLA-A * 0201 , (Lin et al., 1990)), using the DEAE-dextran method.
- COS-7 cells were seeded in 96-wells flatbottom plates at 1.5x10 4 cells per well in 100 ⁇ l DMEM, 8% FCS.
- cDNA clone 4H8 Deletion constructs of cDNA clone 4H8 were obtained by PCR. PCR products were cloned in vector pCR3.uni (TA cloning system, Invitrogen). The constructs pCR-246 and pCR-464 were made with the vector-based forward primer, SP6F-pSV (SEQ ID NO: 13) and the reverse primers in cDNA 4H8, R1 (SEQ ID NO: 14) and R2 (SEQ ID NO: 15) respectively.
- CTL reactivity against tumor target cells transfected COS-7 or peptide loaded cells was measured in a TNF- ⁇ release assay.
- Target cells were seeded in duplicate or triplicate at 1.5-2x10 4 cells per well in a 96-wells flat bottom plate and 1500-2000 CTL were added to each well, in a total volume of 100 ⁇ l / well (IMDM, supplemented with antibiotics and 5% FCS). After 24 hours of co-culturing of effector and target cells, 50 ⁇ l out of each well was added to a fresh 96-wells flatbottom plate, containing 50 ⁇ l
- TNF- ⁇ -sensitive WEHI-164 cells per well in IMDM, supplemented with antibiotics, 5% FCS, 2 ⁇ g/ml Actinomycin D and 40 mM LiCI.
- a viability staining was performed 24 hours later by the addition of 50 ⁇ l of 3-(4,5dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) solution (2.5 mg/ml in PBS). After incubation for 2-4 hours at 37°C the OD5 50 - 6 5 0 was measured.
- TNF- ⁇ release in pg/ml was calculated from a standard with known TNF- ⁇ concentrations.
- cDNA synthesis was performed using oligo-dT and M-MLV reverse transcriptase (Promega). Primers used for LAGE-1 specific PCR were the F3 (SEQ ID NO: 17) and ESO-1 B primer (SEQ ID NO: 18). ESO-1 B was also used as a reverse primer in the NY-ESO-1 -specific PCR, while ESO-1A (SEQ ID NO: 19) was the forward primer in this reaction (Chen et al., 1997). Reactions were performed in a Biometra-Uno or -Trio programmed as follows: 5 minutes 95°C, 30 cycles of 1 min. 95°C, 1 min. 58°C, 1 min. 72°C, followed by 10 minutes 72°C.
- a fragment containing the coding sequence of CAMEL was made by PCR with the following primers:
- 4H8-A GAAGAACATATGCTGATGGCCCAGGAGGC (SEQ ID NO: 20)
- 4H8-C TTAAAGATCTCAGAACCGCCCCTGGTCG (SEQ ID NO: 21)
- This fragment was digested with Ndel and Bglll and cloned in the Ndel and BamHI sites of vector pET19b (Novagen, Madison, Wl).
- This vector contains a 6xHis-tag coding sequence, allowing detection of the His-tagged protein with an anti-His antibody.
- Antibodies against the CAMEL protein were raised by immunizing two rabbits with three synthetic peptides derived from hydrophobic regions of this molecule :
- F4 (K)GAMLAAQERRVPRAAEV(K) (pos. 15-31 of SEQ ID NO: 2)
- A5 (K)GQQGPRGREEAPRGVRM(K) (pos. 36 -52 of SEQ ID NO: 2)
- B5 (K)KRRMEGAPAGPGGRTAA(K) (pos. 58 -73 of SEQ ID NO: 2) (The lysine residues at both termini enable the peptides to be linked to KLH.)
- each peptide was linked chemically to 2.5 mg of the carrier molecule KLH (Keyhole Limpet Hemocyanin) and after dialyzing, 0.8 mg of this protein in CFA (Complete Freund's Adjuvants) was weekly injected subcutaneously.
- CFA Complete Freund's Adjuvants
- Another rabbit was injected six times with the three peptides, not linked to KLH, following the scheme of 300 ⁇ g s.c. in CFA, 300 ⁇ g s.c. in IFA, 4x boost of 150 ⁇ g.
- the reactivity and specificity of the antisera were confirmed in ELISA and Western blot experiments.
- antisera of both rabbits were reactive with the recombinant CAMEL protein synthesized in E.coli, but differed in their precise epitope: rabbit no. 1 produced antibodies against the CAMEL-B5 peptide, whereas the serum of rabbit no. 2 reacted with peptide F4.
- the antisera will further be referred to as "antiserum B5" and "antiserum F4".
- the CAMEL coding sequence was fused to the Aequorea victoria -derived Green Fuorescent Protein (GFP).
- the CAMEL cDNA molecule was cloned into the pEGFP-N1 vector (Clontech), which contains a cDNA encoding the Enhanced, red shifted variant of GFP.
- pEGFP-N1 vector (Clontech)
- two primers were designed.
- the forward primer designated CAMEL-XHO covers the initiation codon ATG and contains an Xho1 site and the reverse primer CAMEL-KPN (AAGGJACCTTGAACCGCCCCTGGTCG; SEQ ID NO: 23) contains a mutation of the stop-codon and a Kpn1 site.
- the vector carrying the fusion construct was transfected into COS cells by calcium phosphate precipitation, protein lysates of the cells were used for Western blotting using CAMEL antisera against the CAMEL peptides B5 and F4, and anti- EGFP antibodies to detect the fusion protein according to standard protocols.
- cDNA clone 4H8 encodes the target for melanoma-specific CTL1/29
- the antigenic epitope of melanoma-specific CTL 1/29 was identified by the expression of cDNA library 518/IL2.14 and the restriction element HLA- A*0201 in COS-7 cells, followed by CTL screening in a TNF- ⁇ release assay.
- a positive pool of cDNAs was subcloned and clone 4H8, called CAMEL (SEQ ID NO: 1), was found to stimulate TNF- ⁇ release by the CTL to a similar extent as the original 518/IL2.14 cell line (Fig. 1).
- COS-7 cells or COS-7 cells transfected with HLA-A * 0201 or the 4H8 cDNA only were not recognized.
- the isolated 4H8 cDNA clone has a 679 bp insert, which shows strong homology with NY-ESO-1 (SEQ ID NO: 7), a tumor antigen originally identified as a target for humoral immune responses by serum screening methods (SEREX) (Chen et al., 1997).
- Colony hybridization of the cDNA library, using clone 4H8 as a probe resulted in the detection of 2 types of full length clones which were called LAGE-1 s (SEQ ID NO: 3) and LAGE-1 L (SEQ ID NO: 5) (Fig. 2a).
- LAGE-1 L contains a 229 bp insertion at position 457, which has the consensus sequences for an intron, starting with a 5' GT and ending 3' AG. This indicates alternative splicing of LAGE-1 mRNA. However, cDNA clone 4H8 lacks the first 84 bp of the LAGE-1 cDNA sequence.
- the peptide epitope of CTL 1/29 is coded in an alternative reading frame of LAGE-1 or NY-ESO-1
- deletion constructs of cDNA 4H8 were transfected in HLA-A*0201 + COS-7 cells and tested in a TNF- ⁇ release assay. CTL reactivity was measured with all constructs (Fig. 1 b), indicating that the epitope was coded within the first 330 bp of clone 4H8.
- An HLA-A * 0201 binding motif search was performed on the predicted protein sequence of that region (Drijfhout et al., 1995; D'Amaro et al., 1995), presuming that the ATG at position 10 in 4H8 functions as the translation initiation site.
- cDNA clone 4H8 lacks the first 84 bp of the LAGE-1 s sequence, which means that it is devoid of the initiation codon at position 54 of that sequence (Fig. 2a).
- the first possible translation initiation site in 4H8 corresponds with the ATG at position 94 of LAGE-1 s , which is however, not in frame with the first ATG at position 54. Therefore, the protein translated from the 4H8 cDNA clone is different from the putative LAGE-1 protein, since translation takes place in another reading frame (Fig. 2a and b).
- 4H8 encodes a protein of 109 amino acids (SEQ ID NO: 2) with a predicted molecular weight of 11.7 kD.
- the LAGE-1 s protein translated from the first ATG will be a 180 aa protein of 18.2 kD (SEQ ID NO: 4), while the unspliced variant, LAGE-1 L , encodes a 210 aa protein of 21.1 kD (SEQ ID NO: 6).
- NY-ESO-1 protein (SEQ ID NO: 8) is probably of the same size as LAGE-1 s , but differs at 26 amino acids. However, if translation of LAGE- 1 S/L starts at the second ATG, proteins will be translated in another reading frame and are in that case identical to the protein translated from cDNA 4H8.
- COS/HLA-A * 0201 cells transfected with LAGE-1 s the alternatively spliced LAGE-1 L (as well as with the NY-ESO-1) cDNA are able to stimulate CTL 1/29 (Fig. 4).
- CTL 1/29 Fig. 4
- protein translation also starts from the second start codon at nucleotide 94 in LAGE-1 s , notwithstanding the presence of the first ATG at position 54. Also in this case, this results in the "alternative reading frame" peptide, MLMAQEALAFL, recognized by CTL 1/29.
- the CAMEL cDNA (SEQ ID No: 1) was cloned in a bacterial expression vector (pET19b) (Studier et al., 1990). This vector contains a 6xHis-tag coding sequence, allowing detection of the His-tagged protein with an anti-His antibody.
- the pET19b-CAMEL construct was transformed into E.coli and the bacteria were treated with IPTG to induce expression of the His-tagged CAMEL protein. Extracts were analyzed by Western blotting using the Penta-His antibody. Western blotting of a lysate shows a 15.5 kD protein, only slightly higher than the expected 14.5 kD of the His-tagged CAMEL protein after staining with a anti-His antibody (Hg. 5).
- the CAMEL cDNA (SEQ ID No: 1) was cloned in pET19b and expressed in E.Coli. Lanes 1 and 2 represent the samples taken at Oh, lanes 3 and 4 at 4h after induction with IPTG. Because CAMEL might be an unstable protein, induction of protein expression was performed in the absence
- Hybridisation of Multiple Tissue Northern blots containing RNA of healthy human tissues with the LAGE-1 s cDNA showed high expression in testis and placenta and low, (but clear) expression in heart, skeletal muscle and pancreas (Fig. 6a).
- the positive signals exist of two bands, probably reflecting LAGE-1 s /NY-ESO-1 (750 bp) and LAGE-1 L (1000 bp).
- LAGE-1 mRNA was detected in a panel of tumor cell lines and tumor tissues and in a restricted number of healthy tissues by means of RT-PCR and Northern blot experiments. However, it remained to be determined whether in cells expressing the LAGE-1 mRNA also the alternatively translated CAMEL is produced.
- CAMEL expression was detected. About half of the positive cases showed expression of CAMEL in 40% or more of the tumor cells, in some of the cases close to 100% of the tumor cells showed CAMEL-specific staining (an example is shown Figure 7, Colon AC). In the majority of tumor specimens expression was heterogeneous ranging from less than 10% of positive tumor cells to more than 70% of positive tumor cells (Table 2; examples are shown in Figure 7, arrows indicate positive tumor cell staining).
- CAMEL SEQ ID NO:2
- FLMAQGAML SEQ ID NO: 24
- CAMEL16 AMLAAQERRV
- CAMEL17 MLAAQERRV (SEQ ID NO:26)
- HLA-A2 restricted CTL-epitopes from CAMEL (MLMAQEALAFL, SEQ ID NO:11) or tyrosinase (W ⁇ lfel et al., 1994; YMNGTMSQV, SEQ ID NO:27) were applied.
- Negative controls included an HLA-A1 binding (and therefore irrelevant) peptide from MAGE-3 (Gaugler et al. , 1994; EVDPIGHLY, SEQ ID NO:28) or no peptide at all.
- CAMEL10 binds with similar affinity to HLA-A2 as compared to the positive controls used in the assay.
- the two other peptides (CAMEL16 and CAMEL17) showed only low affinity in this assay. Therefore in particular CAMEL10 represents a potential new HLA-A2 restricted CTL-epitope derived from CAMEL protein (FIG. 8).
- Murine interleukine-4 displays potent anti-tumour activity in vivo. Cell 57, 503-512.
- van Elsas A., van der Minne, C.E., Borghi, M., van der Spek, C.W., Braakman, E., Osanto, S., and Schrier, P.I. (1996).
- Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccine. Journal of Immunotherapy 20, 343-353.
- c-Myc downregulates class I HLA expression in human melanomas. EMBO J. 7, 1023-1029.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The tumor-associated antigen CAMEL and DNA encoding it. The tumor-associated antigen is encoded by an open reading frame of the LAGE-1 gene. The tumor-associated antigen, immunogenic (poly)peptides derived therefrom and DNAs encoding them, are useful for cancer immunotherapy.
Description
CAMEL, AN ALTERNATIVE TRNSLATION PRODUCT OF THE TUMOUR ANTIGEN LAGE-1
The present invention relates to the field of cancer therapy, more specifically to tumor-associated antigens.
Cytotoxic T lymphocytes (CTLS) play an important role in the defense against melanoma. Melanoma-specific CTL clones have been obtained from either tumor infiltrating lymphocytes (TIL) in vitro stimulated with cytokines, or from peripheral blood mononuclear cells (PBMC) cultured with (autologous) tumor cells. T cell responses against tumor cells are enhanced by cytokine transfection of the tumor cells, both in animal models and in in vitro human culture systems, (van Elsas et al., 1997; Gansbacher et al., 1990; Tepper et al., 1989; Fearon et al., 1990; Dranoff et al., 1993)
The antigens recognized by the tumor-specific T cells become better defined by the development of molecular cloning techniques. These T cell targets can be divided in three groups: 1) tumor-specific antigens, not expressed in healthy tissues, except testis and placenta (e.g., MAGE, BAGE, GAGE, NY-ESO-1 , LAGE-1); 2) antigens that are lineage-specific and expressed in both melanoma and melanocytes (e.g., MART-1/ Melan- A, gp100, tyrosinase) and 3) unique, mutated antigens (e.g., β-catenin, CDK4, MUM-1) (reviewed by Van den Eynde and Brichard, 1995).
By means of Representational Difference Analysis (RDA), a PCR-based method that has been used to identify genes with tissue-specific or tumor- specific expression, the LAGE-1 and NY-ES01 genes were identified as being tumor specific by screening cDNA libraries from melanoma cell lines with a primer from a cDNA clone enriched in melanoma-specific sequences (Lethe et al., 1998).
NY-ESO-1 is a gene originally identified by SEREX technology (Chen et al., 1997). It was shown to have two different reading frames (DNA sequences and derived protein sequences given in SEQ ID NO: 7 - 10), translation
products of which were shown to contain epitopes of tumor specific T-cells (Jager et al., 1998; Wang et al., 1998).
It was an object of the present invention to provide a novel tumor- associated antigen.
To solve the problem underlying the invention, melanoma cell line 518A2 and its IL-2- or GM-CSF-transfectants were compared for their CTL stimulating capacity in vitro. Stimulation of autologous PBMC with the IL-2 producing melanoma cells resulted in a melanoma-specific CTL response (van Elsas et al., 1997). CTL clones derived from this culture recognized, besides autologous melanoma cell lines, also a panel of HLA-A*0201 positive melanoma cell lines, but were not reactive with normal melanocytes. Although 518A2 was shown to express a number of antigens previously identified to be recognized by anti-melanoma CTL (van Elsas et al., 1996), the CTL clones available recognize a new melanoma-specific antigen that is immunodominant in 518A2.
In the experiments of the present invention, the target structure that was recognized by one of these CTL clones was fully characterized and named CAMEL (CTL-recognized Antigen on Melanoma). These sequences are described in the attached sequence listing as SEQ ID NO: 1 and SEQ ID NO: 2.
It was surprisingly found that CAMEL is encoded by a reading frame of the LAGE-1 s-cDNA (SEQ ID NO:3) that is distinct from that encoding the putative LAGE-1 protein (SEQ ID NO: 4). (This reading frame is designated ORF-1.)
In the present invention, a cDNA clone was identified that lacks the first 84 bp of the LAGE-13 sequence (SEQ ID NO: 3) which means that it is devoid of the initiation codon at position 54 of that sequence (Fig. 2a). The first possible translation initiation site in this clone (4H8) is the ATG at position 94 of LAGE-1 s (SEQ ID NO: 3), which is however, not in frame with
the first ATG at position 54. Therefore, the CAMEL protein (SEQ ID NO: 2) translated from the 4H8 cDNA clone is different from the putative LAGE-1 s protein (SEQ ID NO: 4).
In a first aspect, the present invention is directed to the tumor-associated antigen CAMEL (SEQ ID NO: 2) which is encoded by an isolated DNA molecule with the sequence as defined in SEQ ID NO: 1.
The coding sequence of CAMEL corresponds to the ORF-1 of LAGE-1 cDNA (Lethe et al., 1997; WO 98/32855).
In the present invention „ORF-1" is defined as the open reading frame starting with ATG at position 94 of SEQ ID NO:3 (LAGE-1 s), which corresponds to position 10 in SEQ ID NO: 1 (CAMEL), to position 96 in SEQ ID NO: 5 (LAGE-1 L)
In a further aspect, the present invention relates to immunogenic (poly)peptides derived from CAMEL. A first group of peptides is selected from peptides inducing a humoral immune response (induction of antibodies). Such peptides are selected by randomly choosing continuous stretches of amino acids (at least 12-15), applying them to an individual and confirming the generation of antibodies by standard immunological assays, e.g. ELISA. This group of immunogenic (poly)peptides also encompasses the entire CAMEL antigen or larger fragments thereof.
The second group of peptides, which is preferred, can be presented by MHC molecules (in humans: HLA molecules), they have the potential to induce an immune response, in particular by eliciting a CTL response.
In a preferred embodiment, immunogenic peptides which have the ability to elicit a CTL response, are selected from peptides with the sequence set forth in SEQ ID NO: 11 , 12, 24, 25 and 26.
To obtain peptides that have the ability to elicit a cellular immune response, the selection of peptide sequences from a given antigen is, in the first place, based on the requirement for such peptide to bind to an MHC molecule present in the repertoire of the patient to be treated. Two classes of MHC molecules are distinguished, class I and class II. Class I molecules consist of a membrane-inserted heavy chain and a non-covalently attached light chain. In their structure, MHC class I molecules resemble a moose's head, the antlers forming a groove which is recognized by the peptide. In humans, HLA-A, B and C are the "classical" MHC class I molecules.
Additional immunogenic peptides may be identified by methods known in the art which rely on the correlation between MHC-binding and CTL induction, e.g. those used by Stauss et al., 1992, who identified candidate T-cell epitopes in human papilloma virus.
Since immunogenic peptides can be predicted based on their "peptide binding motif" synthetic peptides which represent CTL epitopes may be designed and synthesized. Several methods, which are useful in the present invention for designing peptides, have been used to identify CTL epitopes from known protein antigens.
It is well established that every MHC class I allelic product has allele-specif ic requirements for the peptide ligand that binds to its groove and that it ultimately presents. These requirements were summarized as a motif by Falk et al., 1991. A large number of MHC peptide motifs and MHC ligands have become known to date. A method to search a known protein sequence for epitopes fitting to a given class I molecule, which is based on this knowledge and which may be used in the present invention, was reviewed by Rammensee et al., 1995. It comprises the following steps: first, the protein sequence is screened for stretches fitting to the basic anchor motif (two anchors in most cases), whereby allowance should be made for some variation in peptide lengths as well as in anchor occupancy. If a motif, for example calls for 9mers with lie or Leu at the end, 10mers with
a fitting C-terminus should be considered as well, and other aliphatic residues at the C-terminus, like Val or Met, should also be considered. In this way, a list of peptide candidates is obtained. These are inspected for having as many non-anchor residues as possible in common with ligand already known, or with the residues listed among the "preferred residues" or "others" on top of each motif (Table, given by Rammensee et al., 1995), for various HLA molecules. Binding assays can be performed at this stage to exclude weak binders which occur frequently among peptides conforming to a basic motif. If a detailed study on peptide binding requirements is available, the candidates can also be screened for non-anchor residues detrimental or optimal for binding (Ruppert et al., 1993). One should keep in mind, however, that pure peptide binding motifs can be misleading in the search for natural ligands, since other constraints, such as enzyme specificity during antigen processing and specificity of transporters or chaperones, are likely to contribute to ligand identity in addition to the MHC binding specificity.
This approach was successfully applied by, inter alia, Kawakami et al., 1995, to identify gp100 epitopes based on known HLA-A2.1 motifs. The validity of the method was confirmed by identifying, in parallel, the epitope regions by using COS cells transfected with cDNA fragments generated by sequential deletion and testing for T-cell reactivity, as described above.
Recently, data bases and prediction algorithms have become available that enable to predict, with great reliability, peptide epitopes that bind to HLA molecules of interest.
Examples for peptide candidates with potential immunogenicity that can be derived from the tumor-associated antigen of the present invention, are the CAMEL-derived peptides with the sequence HLSPDQGRF and LMAQEALAF for HLA-A3 or RMAVPLLRβ for HLA-A3101. Similarly, other peptides for these or for other alleles can be determined by the method mentioned above.
The peptide binding can be tested in peptide binding assays. In order to determine the immunogenicity of the selected peptide or peptide equivalent, as defined below, which is the crucial parameter for peptide-based vaccine development and which in most cases strongly correlates with the stability of the peptide-MHC interaction (van der Burg et al., 1996), the methods described by Sette et al., 1994, in combination with quantitative HLA-binding assays, may be used. Alternatively, immunogenicity of the selected peptide may be checked by performing in vitro CTL induction by known methods e.g. as described below for ex vivo CTL induction.
Alternatively to peptides derived from the naturally expressed tumor antigens, functional equivalents thereof, i.e. peptides with partially altered sequences or substances mimicking peptides, e.g. "peptidomimetics" or retro-inverso peptides, may be obtained by the following methods:
To enhance the immunogenicity of the peptides, amino acid substitutions may be introduced at anchor positions to increase peptide MHC class I- binding affinity. The modified peptides are subsequently evaluated for enhanced binding and immunogenicity by screening for recognition by TIL (tumor-infiltrating lymphocytes) and CTL induction as described by Parkhurst at al, 1996, and Bakker et al., 1997.
Another method useful in the present invention to find more immunogenic peptides by screening peptide libraries with a known CTL was described by Blake et al. 1996; it suggests the use of combinatorial peptide libraries for constructing functional mimics of tumor epitopes recognized by MHC class l-restricted CTLs.
In principle, the selection of peptides capable of eliciting a cellular immune response is carried out in several steps, as described in WO 97/30721 , which disclosure is incorporated herein by reference. In short, the candidates are first tested for their binding ability to an MHC molecule; subsequently good binders are tested for immunogenicity. A general
strategy for obtaining efficient immunogenic peptides has been described by Schweighoffer, 1997.
The polypeptide of the present invention or immunogenic peptides derived from its sequence, respectively, can be produced recombinantly or by peptide synthesis, as described in WO 96/10413, the disclosure of which is incorporated herein by reference. For recombinant production, a DNA molecule encoding the antigen or the CTL peptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell, cultivated under conditions suitable for expression, recovered and purified. For chemical synthesis, various conventional techniques may be used, e.g. commercially available automatic synthesizers.
The tumor antigen of the present invention and the immunogenic peptides derived therefrom or the respective peptide equivalents are useful in cancer therapy, e.g. to induce, in the context of the appropriate MHC presenting molecule, an immunological response to tumors which express the corresponding antigen determinants. The induction of CTLs can be accomplished in vivo or ex vivo.
For in vivo induction of CTLs, a pharmaceutical composition comprising the peptide/antigen is administered to an individual suffering from a tumor associated with the respective tumor antigen in an amount sufficient to elicit an effective CTL response to the antigen-bearing tumor. Thus, the present invention provides pharmaceutical compositions for therapeutic treatment which are intended for parenteral, topical, oral or local administration. Preferably, the compositions are for parenteral administration, e.g. for intravenous, subcutaneous, intradermal or intramuscular application. The peptides/antigens are dissolved or suspended in a pharmaceutically acceptable carrier, preferably an aqueous carrier. The composition may contain additional auxiliary substances, e.g. buffering agents, etc. The peptides may be used alone or in combination with adjuvants, e.g. saponins, alumn, or, in a particularly preferred embodiment, polycations,
like polyarginine or polylysine. The peptides may also be linked to components assisting CTL priming, e.g. T helper peptides, lipids or liposomes or coadministered with such components or with immunostimulating substances, e.g. cytokines (IL-2, IFN-γ). Methods and compositions for preparing and administering pharmaceutical compositions for therapeutic treatments are described in WO 95/04542 and WO 97/30721 the disclosures of which are herein incorporated by reference.
The immunogenic peptides may also be used to elicit a CTL response ex vivo. An ex vivo CTL response to a tumor expressing the antigen is induced by incubating a patient's CTL precursor cells together with antigen presenting cells and the immunogenic peptide. The thus activated CTLs are allowed to mature and expand to effector CTLs which are then readministered to the patient. Alternatively, the tumor antigen may be pulsed onto APCs which present MHC class ll-reactive peptides
(Mayordomo et al., 1995; Zitvogel et al., 1996). A suitable method for loading peptides onto cells, e.g. dendritic cells, is disclosed in WO 97/19169.
The peptides of the invention are preferably applied as a combination of peptides, e.g. different CAMEL-peptides. In an even more preferred embodiment, the peptides of the invention are combined with peptides derived from other tumor antigens, e.g. LAGE-1 and ESO-NY-1. The selection of the peptides is optimized towards covering multiple HLA types in order to be useful for a broad population of patients and/or towards a broad variety of malignancies, which is taken into account by combining peptides from a large variety of tumor antigens. The number of peptides suitable to be combined to yield an efficient therapy may vary within a broad range, e.g. from about 2 to approximately 100.
In a further aspect, the present invention is directed to an isolated DNA molecule with the sequence set forth in SEQ ID NO: 1 encoding CAMEL.
This DNA molecule, which is designated "CAMEL-DNA", contains the ORF-1 of LAGE-1 cDNA which is defined by nucleotides 54 - 336 of the sequence set forth in SEQ ID NO: 3.
The CAMEL-DNA of the present invention, or the corresponding RNA, may be used, as an alternative to the use of the protein or the peptide, for cancer immunotherapy. Alternatively to using the natural sequence or fragments thereof, engineered derivatives may be utilized. These include sequences modified to encode (poly)peptides with improved immunogenicity, e.g. taking into account the modifications described above for the peptides. Another form of modification is the assembly of multiple sequences encoding immunologically relevant peptides in a so-called string-of-beads fashion, as described by Toes et al., 1997. The sequences may also be modified by adding auxiliary coding elements, e.g. targeting functions that ensure more efficient delivery and processing of the immunogen (e.g. Wu et al., 1995).
The nucleic acid molecules may be delivered either directly or as part of a recombinant virus or bacterium. In principle, any method that is known for gene therapy may be applied for nucleic acid-based cancer immunotherapy, both in vivo and ex vivo.
Examples for in vivo delivery are direct injection (injection of "naked" DNA) either intramuscularly or by "gene gun", which has been shown to result in the generation of CTLs against tumor antigens. Examples for recombinant organisms are vaccinia virus, fowlpox virus and adenovirus or Listeria monocytogenes (see Coulie, 1997 for a comprehensive review). Furthermore, synthetic nucleic acid carriers like cationic lipids, microspheres, microbeads, liposomes may be useful for in vivo delivery of the sequence encoding respective antigen/peptide. Similarly as for peptides, various auxiliary agents that enhance the immune response may be co-applied, e.g. cytokines, either as proteins or as plasmids encoding these.
Examples for ex vivo delivery are transfection of dendritic cells (Tuting, T., 1997) or other antigen presenting cells which are applied as a cellular cancer vaccine.
The present invention is also directed to the use of cells that express the tumor-associated antigen of the invention, either naturally or upon transfection with the respective coding sequence, for the preparation of a tumor vaccine.
In the present invention, it has been shown that CTL clones raised against IL-2 producing melanoma cell line 518/IL-2.14 are reactive against two alternatively spliced variants of LAGE-1 , LAGE-1 s (SEQ ID NO: 3) and LAGE-1 L (SEQ ID NO: 5) and NY-ESO-1 (SEQ ID NO: 9). NY-ESO-1 is a recently described tumor antigen, identified by screening a cDNA library of an esophagus carcinoma with autologous patient serum (SEREX-method (Chen et al., 1997)). NY-ESO-1 is expressed in different tumor types but not in healthy tissues except the testis.
In the present invention, the epitope of specific CTL 1/29 was determined by cDNA expression cloning and a truncated LAGE-1 cDNA clone was found. This truncation led to the identification of the peptide epitope in an alternative reading frame, since the "normal" translation initiation site of LAGE-1 was absent. However, COS/HLA-A*0201 cells transfected with full length LAGE-1 or NY-ESO-1 cDNA clones could stimulate the CTL clone to TNF- production as well. This probably means that two different proteins can be translated from one single mRNA.
NY-ESO-1 also has been described as the target of melanoma-specific HLA-A*0201 restricted CTL clones, which recognize an epitope translated in ORF3, located between aa 155 and 167 (Jager et al., 1998). Therefore, it is very likely that also LAGE-1 s will be recognized by these clones, but not LAGE-1 L, since the protein sequence is different at this part of the molecule. The CAMEL-specific CTL clones recognize a peptide in an
alternative reading frame, which is encoded in both LAGE-1 and NY-ESO- 1. This means that tumor cells expressing either LAGE-1 or NY-ESO-1 can be recognized by MLMAQEALAFL-specific CTL, which might enlarge the number of tumors that can be treated with immunotherapy based on this peptide.
Brief description of the Figures:
Figure 1 : COS-7 transfection experiments with cDNA clone CAMEL and deletion constructs
a) COS-7 cells were transfected with cDNAs as indicated and tested with CTL 1/29 in a TNF-α release assay.
b) Deletion constructs of CAMEL cDNA were cotransfected with HLA- A*0201 cDNA in COS-7, followed by a TNF-α release assay with CTL 1/29. The PCR clones contain the numbers of nucleotides of the CAMEL cDNA as indicated.
Figure 2:
a) Nucleotide alignment of cDNA clones CAMEL, LAGE-1 s, LAGE-1 Land NY-ESO-1.
b) Protein translations of the cDNA clones LAGE-1 s, LAGE-1 L and NY- ESO-1. The translation of CAMEL is identical to the translation of
LAGE-1 S/L in ORF1. Although ORF3 seems the most putative one, the CTL epitope is encoded in ORF1 (underlined).
Figure 3: Characterisation of peptides recognized by CTL clone 1/29
a) TNF-α release assay with predicted HLA-A*0201 binding CAMEL peptides. Peptides as indicated were loaded on BLM, an
HLA-A*0201+ melanoma cell line, at a concentration of 10 μg/ml and tested with CTL 1/29 in a TNF-α release assay.
b) The effects of increasing concentrations of peptides, derived from the major target epitope MLMAQEALAFL on recognition by CTL 1/29. Various concentrations of peptides as indicated were loaded on
HLA-A*0201+ cells and tested in a TNF-α release assay with CTL 1/29.
Figure 4: LAGE-1 S L and NY-ESO-1 encode the CTL epitope
COS/HLA-A*0201 cells were transfected with these cDNA clones and reactivity with CTL 1/29 was measured in a TNF-α release assay.
Figure 5: His-tagged CAMEL protein, synthesized in E.coli
Figure 6: Expression of LAGE-1 S/L and NY-ESO-1 in healthy human tissues and melanoma cell lines
a) Northern Blot analysis of the expression of LAGE-1/NY-ESO-1 in a panel of healthy human tissues as indicated. The Blot was hybridised with 32P-dCTP-labeled LAGE-1 s cDNA.
b) RT-PCR for LAGE-1 and NY-ESO-1. To discriminate between LAGE-1 and NY-ESO-1 mRNA, the same panel of melanoma cell lines was analysed by RT-PCR with gene-specific primers. Melanoma cell lines as indicated were used as targets in a TNF-α release assay with CTL 1/29.
Figure 7: Immunohistochemical analysis of CAMEL expression in human tumors
Figure 8: Stabilization of HLA-A2 surface expression by synthetic peptides on T2-cells
Brief description of the sequences:
SEQ ID NO: 1 : CAMEL (4H8) cDNA sequence and translation
SEQ ID NO: 2: CAMEL protein sequence SEQ ID NO: 3: LAGE-1 s cDNA sequence and translation
SEQ ID NO: 4: LAGE-1 s protein sequence
SEQ ID NO: 5: LAGE-1 L cDNA sequence and translation
SEQ ID NO: 6: LAGE-1 L protein sequence
SEQ ID NO: 7: NY-ESO-1 cDNA sequence and translation SEQ ID NO: 8: NY-ESO-1 protein sequence
SEQ ID NO: 9: NY-ESO-1 cDNA and alternative translation
SEQ ID NO: 10: protein sequence of alternatively translated NY-ESO-1
SEQ ID NO: 11 : peptide sequence of the CAMEL CTL epitope (11 -mer)
SEQ ID NO: 12: peptide sequence of the CAMEL CTL epitope (10-mer) SEQ ID NO: 13: oligonucleotide SP6F-pSV
SEQ ID NO: 14: oligonucleotide R1
SEQ ID NO: 15: oligonucleotide R2
SEQ ID NO: 16: oligonucleotide T7R-pSV
SEQ ID NO: 17: oligonucleotide F3 SEQ ID NO: 18: oligonucleotide ESO-1 B
SEQ ID NO: 19: oligonucleotide ESO-1A
SEQ ID NO: 20: oligonucleotide 4H8-A
SEQ ID NO: 21 : oligonucleotide 4H8-C
SEQ ID NO: 22 oligonucleotide CAMEL-XHO SEQ ID NO: 23 oligonucleotide CAMEL-KPN
SEQ ID NO: 24 peptide CAMEL10 SEQ ID NO: 25 peptide CAMEL16 SEQ ID NO: 26 peptide CAMEL17 SEQ ID NO: 27 tyrosinase peptide SEQ ID NO: 28 MAGE-3 peptide
In the Examples, if not stated otherwise, the following materials and methods were used
a) Cell cultures
Melanoma cell lines and COS-7 cells were maintained in DMEM containing 4.5 mM glucose supplemented with 8% FCS, 2 mM L-glutamine, 100 μg/ml of each penicillin and streptomycin. Melanoma cell line 518A2 was established from the dissected metastasis of a male patient in 1985, as described before (Versteeg et al., 1988). An IL-2 producing variant, 518/IL- 2.14, was obtained by transfection of 518A2 with the IL-2 cDNA (Osanto et al., 1993). Other melanoma cells that were used as targets in TNF-α release assay are FM3.29, FM6, FM28.4 and FM55P (gifts from J. Zeuthen, Denmark), MM127, MM415, MM485 (gifts from N. Hayward, Australia), SK- MEL-23, SK-MEL-29 (obtained from T. Wolfel, Mainz), MM0221 , Mi3046/2, NA8, BLM (obtained from M. Visseren, Leiden). EBV-transformed B-LCL and the TNF-α-sensitive WEHI-164 clone 13 (a gift from Dr. P. Coulie, Brussels) were cultured in RPMI-1640, supplemented with L-glutamine and antibiotics as above, and 10% FCS.
With the IL-2 producing cell line 518/IL-2.14 and autologous peripheral blood mononuclear cells (PBMC) a CTL induction was performed, resulting in melanoma-specific HLA-A*0201 restricted CTL clones (van Elsas et al., 1997). The identification of the epitope of one of these clones, CTL 1/29, is reported here.
b) cDNA expression cloning
A cDNA library of 518/IL-2.14 was constructed in the expression vector pSVsportl (GIBCO, BRL) using the Superscript Plasmid System (GIBCO, BRL). As to that purpose, poly-A+ mRNA was isolated using the Fast-Track system (Invitrogen), followed by reverse-transcription with an oligo-dT/Notl primer. Sail adapters were ligated to ds-cDNA and after Notl digestion and size fractionation, cDNA fragments were cloned into the pSVsportl vector digested with Sail and Notl. After electroporation into ElectroMAX-DH10B (GIBCO, BRL) (following the manufacturers instructions) and selection for ampicilin resistance, 50-100 colonies were pooled for mini DNA isolation (QIAprep 8 plasmid kit, Qiagen). The in this way obtained cDNA pools were transfected in duplicate into COS-7 cells, together with the restriction element HLA-A*0201 (pBJ1.neo/HLA-A*0201 , (Lin et al., 1990)), using the DEAE-dextran method. Briefly, COS-7 cells were seeded in 96-wells flatbottom plates at 1.5x104 cells per well in 100 μl DMEM, 8% FCS. After 2 hours, medium was replaced by 30 μl transfection mixture, containing 100 ng cDNA pool, 100 ng HLA-A*0201 cDNA, 400 ng/ml DEAE-dextran and 100 μM chloroquine in serum free DMEM. Cells were incubated for 4 hours at 37°C and shocked for 2 minutes by the addition of 50 μl 10% DMSO in PBS. The shock medium was replaced by 200 μl DMEM, 8% FCS, and 48 hours later the cells were used as target cells for CTL in a TNF-α release assay.
c) Deletion constructs
Deletion constructs of cDNA clone 4H8 were obtained by PCR. PCR products were cloned in vector pCR3.uni (TA cloning system, Invitrogen). The constructs pCR-246 and pCR-464 were made with the vector-based forward primer, SP6F-pSV (SEQ ID NO: 13) and the reverse primers in cDNA 4H8, R1 (SEQ ID NO: 14) and R2 (SEQ ID NO: 15) respectively. As a control the complete 679 bp cDNA was cloned by PCR with two primers
on the pSVsport vector, SP6F-pSV (SEQ ID NO: 13) and T7R-pSV (SEQ ID NO: 16), resulting in pCR-679.
d) TNF-α release assay
CTL reactivity against tumor target cells, transfected COS-7 or peptide loaded cells was measured in a TNF-α release assay. Target cells were seeded in duplicate or triplicate at 1.5-2x104 cells per well in a 96-wells flat bottom plate and 1500-2000 CTL were added to each well, in a total volume of 100 μl / well (IMDM, supplemented with antibiotics and 5% FCS). After 24 hours of co-culturing of effector and target cells, 50 μl out of each well was added to a fresh 96-wells flatbottom plate, containing 50 μl
(4.5x104) TNF-α-sensitive WEHI-164 cells per well in IMDM, supplemented with antibiotics, 5% FCS, 2 μg/ml Actinomycin D and 40 mM LiCI. A viability staining was performed 24 hours later by the addition of 50 μl of 3-(4,5dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) solution (2.5 mg/ml in PBS). After incubation for 2-4 hours at 37°C the OD550-650 was measured. TNF-α release in pg/ml was calculated from a standard with known TNF-α concentrations.
e) Northern Blot analysis
To determine expression in healthy tissues a Multiple Tissue Northern Blot was obtained commercially (Clontech). As a probe, LAGE-1 cDNA was used, labeled with γ-32P-dCTP by use of the Mega-Prime Labeling kit (Amersham).
f) RT-PCR
cDNA synthesis was performed using oligo-dT and M-MLV reverse transcriptase (Promega). Primers used for LAGE-1 specific PCR were the F3 (SEQ ID NO: 17) and ESO-1 B primer (SEQ ID NO: 18). ESO-1 B was also used as a reverse primer in the NY-ESO-1 -specific PCR, while ESO-1A (SEQ ID NO: 19) was the forward primer in this reaction (Chen et
al., 1997). Reactions were performed in a Biometra-Uno or -Trio programmed as follows: 5 minutes 95°C, 30 cycles of 1 min. 95°C, 1 min. 58°C, 1 min. 72°C, followed by 10 minutes 72°C.
g) Expression of CAMEL in E. Coli
A fragment containing the coding sequence of CAMEL was made by PCR with the following primers:
4H8-A: GAAGAACATATGCTGATGGCCCAGGAGGC (SEQ ID NO: 20) 4H8-C: TTAAAGATCTCAGAACCGCCCCTGGTCG (SEQ ID NO: 21)
This fragment was digested with Ndel and Bglll and cloned in the Ndel and BamHI sites of vector pET19b (Novagen, Madison, Wl). This vector contains a 6xHis-tag coding sequence, allowing detection of the His-tagged protein with an anti-His antibody. The pET19b-CAMEL construct was transformed into BL21 (DE3)pLysS E. coli bacteria (Novagen, Madison, Wl). After culturing the bacteria at 30°C until an OD6oo =0.5 , IPTG (1 mM) was added to induce overexpression of the His-tagged CAMEL protein.
Samples were taken at Oh and 4h after IPTG induction and lysates of these samples were tested on a Western Blot with the Penta-His Antibody (Qiagen) according to the Western and Colony Blot protocol of the supplier. The His-tagged protein was visualized using the SuperSignal Substrate system for Western blotting (Pierce, Rockford, US).
h) Preparation of anti-CAMEL antisera
Antibodies against the CAMEL protein were raised by immunizing two rabbits with three synthetic peptides derived from hydrophobic regions of this molecule :
F4: (K)GAMLAAQERRVPRAAEV(K) (pos. 15-31 of SEQ ID NO: 2) A5: (K)GQQGPRGREEAPRGVRM(K) (pos. 36 -52 of SEQ ID NO: 2) B5: (K)KRRMEGAPAGPGGRTAA(K) (pos. 58 -73 of SEQ ID NO: 2)
(The lysine residues at both termini enable the peptides to be linked to KLH.)
For rabbit no. 1 , 1 mg of each peptide was linked chemically to 2.5 mg of the carrier molecule KLH (Keyhole Limpet Hemocyanin) and after dialyzing, 0.8 mg of this protein in CFA (Complete Freund's Adjuvants) was weekly injected subcutaneously. Another rabbit (no. 2) was injected six times with the three peptides, not linked to KLH, following the scheme of 300 μg s.c. in CFA, 300 μg s.c. in IFA, 4x boost of 150 μg. The reactivity and specificity of the antisera were confirmed in ELISA and Western blot experiments. After four immunizations, antisera of both rabbits were reactive with the recombinant CAMEL protein synthesized in E.coli, but differed in their precise epitope: rabbit no. 1 produced antibodies against the CAMEL-B5 peptide, whereas the serum of rabbit no. 2 reacted with peptide F4. The antisera will further be referred to as "antiserum B5" and "antiserum F4".
j) Preparation of CAMEL-EGFP fusion proteins
The CAMEL coding sequence was fused to the Aequorea victoria -derived Green Fuorescent Protein (GFP). The CAMEL cDNA molecule was cloned into the pEGFP-N1 vector (Clontech), which contains a cDNA encoding the Enhanced, red shifted variant of GFP. In order to clone the cDNA molecule in frame with the EGFP cDNA and unidirectional, two primers were designed. The forward primer designated CAMEL-XHO (TTACJCGAGATGCTGATGGCCCAGG; SEQ ID NO: 22 ) covers the initiation codon ATG and contains an Xho1 site and the reverse primer CAMEL-KPN (AAGGJACCTTGAACCGCCCCTGGTCG; SEQ ID NO: 23) contains a mutation of the stop-codon and a Kpn1 site. The vector carrying the fusion construct was transfected into COS cells by calcium phosphate precipitation, protein lysates of the cells were used for Western blotting using CAMEL antisera against the CAMEL peptides B5 and F4, and anti- EGFP antibodies to detect the fusion protein according to standard protocols.
Example 1
cDNA clone 4H8 (CAMEL) encodes the target for melanoma-specific CTL1/29
The antigenic epitope of melanoma-specific CTL 1/29 was identified by the expression of cDNA library 518/IL2.14 and the restriction element HLA- A*0201 in COS-7 cells, followed by CTL screening in a TNF-α release assay. A positive pool of cDNAs was subcloned and clone 4H8, called CAMEL (SEQ ID NO: 1), was found to stimulate TNF-α release by the CTL to a similar extent as the original 518/IL2.14 cell line (Fig. 1). COS-7 cells or COS-7 cells transfected with HLA-A*0201 or the 4H8 cDNA only were not recognized. The isolated 4H8 cDNA clone has a 679 bp insert, which shows strong homology with NY-ESO-1 (SEQ ID NO: 7), a tumor antigen originally identified as a target for humoral immune responses by serum screening methods (SEREX) (Chen et al., 1997). Colony hybridization of the cDNA library, using clone 4H8 as a probe resulted in the detection of 2 types of full length clones which were called LAGE-1 s (SEQ ID NO: 3) and LAGE-1 L (SEQ ID NO: 5) (Fig. 2a). LAGE-1 L contains a 229 bp insertion at position 457, which has the consensus sequences for an intron, starting with a 5' GT and ending 3' AG. This indicates alternative splicing of LAGE-1 mRNA. However, cDNA clone 4H8 lacks the first 84 bp of the LAGE-1 cDNA sequence.
Example 2
The peptide epitope of CTL 1/29 is coded in an alternative reading frame of LAGE-1 or NY-ESO-1
To identify which peptide was recognized by CTL 1/29, deletion constructs of cDNA 4H8 were transfected in HLA-A*0201+ COS-7 cells and tested in a TNF-α release assay. CTL reactivity was measured with all constructs (Fig. 1 b), indicating that the epitope was coded within the first 330 bp of
clone 4H8. An HLA-A*0201 binding motif search was performed on the predicted protein sequence of that region (Drijfhout et al., 1995; D'Amaro et al., 1995), presuming that the ATG at position 10 in 4H8 functions as the translation initiation site. Predicted strong binding peptides at regions 1-11 , 2-11 , 1 -9, 10-18, 11-19, 16-25, 17-25, 49-57, 55-63 and 70-78 of the CAMEL protein sequence (Fig. 2b) were added to HLA-A*0201+ BLM melanoma cells, and tested for CTL reactivity in a TNF-α release assay (Fig. 3b).
At a peptide concentration of 10 μg/ml only the N-terminal 11- and 10-mer peptides (M)LMAQEALAFL (SEQ ID NO: 11 and NO: 12) induced preponderant recognition by CTL 1/29 (Fig. 3a), indicating that the epitope recognized by the CTL is located in the first 11 amino acids of the CAMEL- encoded protein. Closer inspection of peptides derived of this N-terminal 11-mer in a peptide concentration dependent TNF-α release assay (Fig. 3b) revealed that the methionine at position 1 as well as the leucine at position 11 are of crucial importance for reconstituting CTL reactivity. Deletion of either of these amino acids leads to an at least 5 decades higher peptide concentration required for comparable TNF-α release. The only other peptide showing weak activity is the 3-11 MAQEALAFL. In contrast, the MLMAQEALA has no activity at all (Fig. 3b), suggesting that the C-terminal amino acids FL do significantly contribute to the recognition by the CTL.
Example 3
Comparison of CAMEL, LAGE-1 S L, NY-ESO-1
As already mentioned, cDNA clone 4H8 lacks the first 84 bp of the LAGE-1 s sequence, which means that it is devoid of the initiation codon at position 54 of that sequence (Fig. 2a). The first possible translation initiation site in 4H8 corresponds with the ATG at position 94 of LAGE-1 s, which is however, not in frame with the first ATG at position 54. Therefore, the protein translated from the 4H8 cDNA clone is different from the putative
LAGE-1 protein, since translation takes place in another reading frame (Fig. 2a and b). 4H8 encodes a protein of 109 amino acids (SEQ ID NO: 2) with a predicted molecular weight of 11.7 kD. The LAGE-1 s protein translated from the first ATG will be a 180 aa protein of 18.2 kD (SEQ ID NO: 4), while the unspliced variant, LAGE-1 L, encodes a 210 aa protein of 21.1 kD (SEQ ID NO: 6). NY-ESO-1 protein (SEQ ID NO: 8) is probably of the same size as LAGE-1 s, but differs at 26 amino acids. However, if translation of LAGE- 1S/L starts at the second ATG, proteins will be translated in another reading frame and are in that case identical to the protein translated from cDNA 4H8. Alternative translation of NY-ESO-1 (SEQ ID NO: 9 and NO: 10) results in a shorter variant of this protein (58 amino acids), because of an earlier stop codon (Fig. 2b), which differs from the CAMEL protein sequence only in its last 5 amino acids (Fig. 2b).
It was examined whether cells transfected with the complete LAGE-1 (or NY-ESO-1) cDNA clones are able to stimulate CTL 1/29. Remarkably,
COS/HLA-A*0201 cells transfected with LAGE-1 s, the alternatively spliced LAGE-1 L (as well as with the NY-ESO-1) cDNA are able to stimulate CTL 1/29 (Fig. 4). This indicates that, at least in COS-7 cells, protein translation also starts from the second start codon at nucleotide 94 in LAGE-1 s, notwithstanding the presence of the first ATG at position 54. Also in this case, this results in the "alternative reading frame" peptide, MLMAQEALAFL, recognized by CTL 1/29.
Example 4
Expression of CAMEL in E. Coli
To investigate whether CAMEL is indeed translated from the ORF-1 of the CAMEL (4H8) cDNA, the CAMEL cDNA (SEQ ID No: 1) was cloned in a bacterial expression vector (pET19b) (Studier et al., 1990). This vector contains a 6xHis-tag coding sequence, allowing detection of the His-tagged protein with an anti-His antibody. The pET19b-CAMEL construct was
transformed into E.coli and the bacteria were treated with IPTG to induce expression of the His-tagged CAMEL protein. Extracts were analyzed by Western blotting using the Penta-His antibody. Western blotting of a lysate shows a 15.5 kD protein, only slightly higher than the expected 14.5 kD of the His-tagged CAMEL protein after staining with a anti-His antibody (Hg. 5).
The CAMEL cDNA (SEQ ID No: 1) was cloned in pET19b and expressed in E.Coli. Lanes 1 and 2 represent the samples taken at Oh, lanes 3 and 4 at 4h after induction with IPTG. Because CAMEL might be an unstable protein, induction of protein expression was performed in the absence
(lanes 1 and 3) or presence (lanes 2 and 4) of PMSF (a protease inhibitor). At the left the positions of the molecular weight marker proteins are indicated.
Example 5
Expression of LAGE-1 and NY-ESO-1 in healthy human tissues and melanoma cell lines
Hybridisation of Multiple Tissue Northern blots containing RNA of healthy human tissues with the LAGE-1 s cDNA showed high expression in testis and placenta and low, (but clear) expression in heart, skeletal muscle and pancreas (Fig. 6a). The positive signals exist of two bands, probably reflecting LAGE-1 s/NY-ESO-1 (750 bp) and LAGE-1 L (1000 bp).
Several melanoma cell lines were tested for expression of LAGE-1 and NY-ESO-1 by(Northern Blot analysis and) RT-PCR (Fig. 6b). Because of the strong homology between both genes, it is not possible to discriminate between LAGE-1 and NY-ESO-1 on Northern Blot. Therefore RT-PCR was performed with specific primers. In most cell lines a correlated expression of LAGE-1 and NY-ESO-1 was found; only cell line FM3.29 had expression of LAGE-1 , but was negative for NY-ESO-1. Other cell lines expressed
either both or none of the two genes (Fig. 6b). There was a good correlation between the level of expression and the recognition by CTL 1/29 (Fig. 6b).
Example 6
Determination of LAGE1/CAMEL expression of in human tumors by RT- PCR
In order to evaluate the percentage of LAGE1/CAMEL positive human tumors, individual tumor tissues from breast or lung cancer patients were subjected to RT-PCR, as described in the Method section f), using the LAG E1 -specific primers F3 (SEQ ID NO: 17) and ESO-1 B (SEQ ID NO: 18); reactions were performed in a Perkin Elmer 9600 thermocycler with 35 (instead of 30) cycles.
As shown in Table 1 , approximately 50% (3/6) of the tested breast cancer specimens and 80% (10/12) of the lung cancer specimens were shown to be positive for LAGE1 /CAMEL mRNA .
Table 1 :
Example 7
Immunohistochemical analysis of CAMEL expression in human tumors
As described in Examples 5 and 6, LAGE-1 mRNA was detected in a panel of tumor cell lines and tumor tissues and in a restricted number of healthy tissues by means of RT-PCR and Northern blot experiments. However, it remained to be determined whether in cells expressing the LAGE-1 mRNA also the alternatively translated CAMEL is produced.
Frozen sections from a panel of different human tumors were analyzed by immunohistochemistry using a CAMEL-specific rabbit antiserum B5 which was affinity-purified against the B5 peptide. (For the preparation of the antisera, see h) in the Methods section. The B5 antiserum was used because B5 is CAMEL-specific, while the F4 antiserum may also recognize an epitope present on a protein expressed from the ORF-1 of NY-ESO-1). Specificity of the purified serum was demonstrated by peptide ELISA and Western blotting against COS cells transfected with a CAMEL-GFP fusion protein. Immunohistochemistry was performed using a 3-step avidin-biotin- peroxidase staining procedure. The results are summarized in Table 2, examples are shown in Figure 7.
Table 2:
AC: adenocarcinoma
SCC: squamous cell carcinoma
A total of 48 different specimen was investigated. In the majority of cases (38/48) CAMEL expression was detected. About half of the positive cases showed expression of CAMEL in 40% or more of the tumor cells, in some of the cases close to 100% of the tumor cells showed CAMEL-specific staining (an example is shown Figure 7, Colon AC). In the majority of tumor specimens expression was heterogeneous ranging from less than 10% of positive tumor cells to more than 70% of positive tumor cells (Table 2; examples are shown in Figure 7, arrows indicate positive tumor cell staining).
Example 8
Identification of HLA-A2 binding peptides within the CAMEL ORF
In order to identify further HLA-A2 epitopes besides the CTL-epitope (M)LMAQEALAFL (SEQ ID NO:11 and 12), CAMEL (SEQ ID NO:2) was examined according to the algorithms and motifs published by Parker et al.;
1994, and Rammensee et al., 1995. The result of this analysis indicated that several further peptides within the CAMEL protein have the potential to bind to HLA-A2, and three of these candidates -CAMEL10: FLMAQGAML (SEQ ID NO: 24), CAMEL16: AMLAAQERRV (SEQ ID NO: 25) and CAMEL17: MLAAQERRV (SEQ ID NO:26) - were synthesized.
These synthetic peptides were evaluated for their ability to increase surface HLA-A2 expression on the transport defective cell Nne174CEM.T2 (Nijman et al., 1993). Briefly, 5x105 cells/0.2 ml/well were seeded in 96-well V-bottom plates and incubated for 16 hours with increasing ammounts (0-320 μg/ml) of peptide at 37°C in a humidified atmosphere. HLA-A2 surface expression was measured by FACS analysis (Becton Dickinson) using purified BB7.2 as primary antibody and a goat-anti-mouse IgG RPE conjugate(DAKO) as detection antibody.
As positive controls the known HLA-A2 restricted CTL-epitopes from CAMEL (MLMAQEALAFL, SEQ ID NO:11) or tyrosinase (Wδlfel et al., 1994; YMNGTMSQV, SEQ ID NO:27) were applied. Negative controls included an HLA-A1 binding (and therefore irrelevant) peptide from MAGE-3 (Gaugler et al. , 1994; EVDPIGHLY, SEQ ID NO:28) or no peptide at all.
The results from these experiments suggest that the nonamer CAMEL10 binds with similar affinity to HLA-A2 as compared to the positive controls used in the assay. The two other peptides (CAMEL16 and CAMEL17) showed only low affinity in this assay. Therefore in particular CAMEL10 represents a potential new HLA-A2 restricted CTL-epitope derived from CAMEL protein (FIG. 8).
The testing of the immunogenicity of CAMEL10 and if it represents a naturally processed and presented ligand can be done as described in WO 97/30721 and Schweighoffer, 1997.
Bibliography
Bakker, A.B.H., van der Burg, S.H., Huijbens, R.J.F., Drijfhout, J.-W., Melief, J.M., Adema, G.J., and Figdor, C.G. (1997). Analogues of CTL epitopes with improved MHC Class-I Binding capacity elicit anti-melanome CTL recognizing the wild-type epitope. Int. J. Cancer 70, 302-309.
Blake, J., Johnston, JN., Hellstrόm, K.E., Marquardt, H., and, Chen, L. (1996). Use of Combinatorial Peptide Libraries to Construct
FunctionalMimics of Tumor Epitopes Recognized by MHC Class I- Restricted Cytolytic T Lymphocytes. J. Exp. Med. 184, 121-130.
Chen, Y.T., Scanlan, M.J., Sahin, U., Tureci, O., Gure, A.O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., and Old, L.J. (1997). A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Νatl. Acad. Sci. U. S. A. 94, 1914-1918.
Coulie P.G. (1997) Human tumour antigens recognized by T cells: new perspectives for anti cancer vaccines. Mol. Med. Today 3, 261-268
D'Amaro, J., Houbiers, J.G., Drijfhout, J.W., Brandt, R.M., Schipper, R., Bavinck, J.Ν., Melief, C.J., and Kast, W.M. (1995). A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. Hum. Immunol. 43, 13-18.
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent,
specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543.
Drijfhout, J.W., Brandt, R.M., D'Amaro, J., Kast, W.M., and Melief, C.J. (1995). Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay. Hum. Immunol. 43, 1-12.
Falk, K., Rόtzschke, O., Stevanovi'c, S., Jung, G., and Rammensee, H-G (1991). Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290-296.
Fearon, E.R., Pardoll, D.M., Itaya, T., Golumbek, P., Levitsky, H.I., Simons, J.W., Karasuyama, H., Vogelstein, B., and Frost, P. (1990). lnterleukine-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403.
Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., and Gilboa, E. (1990). Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
Gaugler B, van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T (1994) J. Exp. Med. 179:921-30
Jager, E., Chen, Y.T., Drijfhout, J.W., Karbach, J., Ringhoffer, M., Jager, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old, L.J., and Knuth, A. (1998). Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1 : definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187, 265-270.
Kawakami, Y., Eliyahu, S., Jennings, C, Sakaguchi, K., King, X., Southwood, S., Robbins, P.F., Sette, A., Appella, E., and Rosenberg, S.A. (1995). Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154, 3961-3968.
Lethe, B., Lucas, S., Michaux, L., Desmet, C, Godelaine, D., Serrano, A., Deplaen, E. and Boon, T. (1998). LAGE-1 , a new gene with tumor specificity. Int. J. Cancer 76 (6):903-908.
Lin, A.Y., Devaux, B., Green, A., Sagerstrom, C, Elliott, J.F., and Davis, M.M. (1990). Expression of T Cell Antigen Receptor Heterodimers in a Lipid-Linked Form. Science 249, 677-679.
Mayordomo, J.I., Zorina, T., Storkus, W.J., Zitvogel, L., Celluzzi, C, Falo, L.D., Melief, C.J., lldstad, ST., Kast, W.M., DeLeo, A.B., and Lotze, M.T. (1995). Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Medicine 1, 1297-1302.
Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ, Kast WM (1993) Eur. J. Immunol. 6: 1215-9
Osanto, S., Brouwenstyn, N., Vaessen, N., Figdor, C.G., Melief, C.J., and Schrier, P.I. (1993). Immunization with interleukin-2 transfected melanoma cells. A phase l-ll study in patients with metastatic melanoma. Hum. Gene Ther. 4, 323-330.
Parker KC, Bednarek MA, Coligan JE (1994), J. Immunol. 152:163
Parkhurst, M.R., Salgaller, M.L, Southwood, S., Robbins, P.F., Sette, A., Rosenberg, S.A., and Kawakami, Y. (1996). Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 -binding residues. J. Immunol. 157, 2539-2548.
Rammensee, H.G. and Friede, T. (1995). MHC ligands and peptide motifs: first listing. Immunogenetics 41, 179-228.
Ruppert, J., Sidney, J., Celis, E., Kubo, R.T., Grey, H.M., and Sette, A. (1993). Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74, 929-937.
Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989). Molecular Cloning, a Laboratory Manual (New York: Cold Spring Harbor Laboratory Press).
Schweighoffer, T. (1997) Molecular cancer vaccines: tumor therapy using antigen-specific immunizations. Path. One. Res. 3, 164-176
Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W.M., Melief, C.J.M., Oseroff, C, Yuan, L., Ruppert, J., Sidney, J., del Guercio, M.-F., Southwood, S., Kubo, R.T., Chesmut, R.W., Grey, H.M., and Chisari, F.V. (1994). The relationship between class I binding affinity and immunogenicity of potentioal cytotoxic T Cell epitopes. J. Immunol. 753, 5586-5592.
Stauss, H.J., Davies, H., Sadovnikova, E., Chain, B., Horowitz., and Sinclair, C. (1992). Induction of cytotoxic T lymphocytes with peptides in vitro: Identification of candidate T-cell epitopes in human papilloma virus. Proc. Natl. Acad. Sci. USA. 89, 7871 -7875.
Studier, F.W., Rosenberg, A.H., Dunn, J.J. and Dubendorf, J.W. (1990). Use of T7 RNA polymerase to direct expression of cloned genes. Methods in Enzymology 185, 60-89
Tepper, R.I., Pattengale, P.K., and Leder, P. (1989). Murine interleukine-4 displays potent anti-tumour activity in vivo. Cell 57, 503-512.
Toes, R.E., Hoeben, R.C., Van der Voort, E., Ressing, M.E., Van-der-Eb, A.J. Melief, C.J.M., and Offringa, R. 1997 Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc. Natl. Acad. Sci. U.S.A. 94 (26): 14660-14665
Tuting, T., DeLeo, A.B., Lotze, M.T., and Storkus, W.J. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur. J. Immunol. 27, 2702-2707, 1997.
van der Burg, S.H., et al., (1996), Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 756, 3308-3314
Van den Eynde, B. and Brichard, V.G. (1995). New tumor antigens recognized by T cells. Current Opinion in Immunology 7, 674-681.
van Elsas, A., van der Minne, C.E., Borghi, M., van der Spek, C.W., Braakman, E., Osanto, S., and Schrier, P.I. (1996). CTL Recognition of an IL-2 Producing Melanoma Vaccine. In: Immunology of human melanoma. Tumor-host interaction and immunotherapy, edited by M. Maio, Amsterdam: IOS, 1996, p. 165-173.
van Elsas, A., Aamoudse, C, van der Minne, C.E., van der Spek, C.W., Brouwenstijn, N., Osanto, S., and Schrier, P.I. (1997). Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccine. Journal of Immunotherapy 20, 343-353.
Versteeg, R., Noordermeer, I.A., Krϋse-Wolters, K.M., Ruiter, D.J., and Schrier, P.I. (1988). c-Myc downregulates class I HLA expression in human melanomas. EMBO J. 7, 1023-1029.
Wang, R.F., Johnston, S.L., Zeng,G., Topalian,S.L., Schwartzentruber.D.J., and Rosenberg,S.A. (1998). A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J. Immunol. 161, 3596-3606.
Wόlfel T, van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Bϋschenfelde KH, Boon T (1994) Eur. J. Immunol. 24:759-64
Wu, T.C., Guamieri, F.G., Staveley-O'Carroll, K.F., Viscidi, R.P., Levitsky, H.I., Hedrick, L, Cho, K.R., August, J.T., and Pardoll, D.M. (1995).
Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. U.S.A. 02(25): 11671 -11675.
Zitvogel, L., Mayordomo, J.I., Tjandrawan, T., DeLeo, A.B., Clarke, M.R., Lotze, M.T., and Storkus, W.J. (1996). Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1 -associated cytokines. J. Exp. Med. 183, 87-97.
Claims
1. Tumor-associated antigen CAMEL which is encoded by the ORF-1 of LAGE-1 cDNA and has the amino acid sequence set forth in SEQ ID NO: 2.
2. The tumor-associated antigen of claim 1 for use in cancer therapy.
3. Immunogenic (poly)peptide derived from the tumor-associated antigen of claim 1.
4. An immunogenic peptide of claim 3, characterized in that it has the amino acid sequence Met Leu Met Ala Gin Glu Ala Leu Ala Phe Leu
(SEQ ID NO: 11).
5. An immunogenic peptide of claim 3, characterized in that it has the amino acid sequence Leu Met Ala Gin Glu Ala Leu Ala Phe Leu (SEQ ID NO: 12).
6. An immunogenic peptide of claim 3, characterized in that it has the amino acid sequence Phe Leu Met Ala Gin Gly Ala Met Leu (SEQ ID NO: 24).
7. An immunogenic peptide of claim 3, characterized in that it has the amino acid sequence Ala Met Leu Ala Ala Gin Glu Arg Arg Val (SEQ ID NO: 25).
8. An immunogenic peptide of claim 3, characterized in that it has the amino acid sequence Met Leu Ala Ala Gin Glu Arg Arg Val
(SEQ ID NO: 26).
9. An immunogenic peptide of any one of claims 3 to 8 for use in cancer immunotherapy.
10. Pharmaceutical composition containing the tumor-associated antigen CAMEL of claim 1.
11. Pharmaceutical composition containing an immunogenic peptide of any one of claims 3 to 8.
12. Isolated DNA molecule comprising the sequence set forth in SEQ ID NO: 1.
13. Recombinant DNA molecule comprising the DNA molecule of claim 12.
14. A DNA molecule of claim 12 or 13 for use in cancer immunotherapy.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99953854A EP1121435A1 (en) | 1998-10-16 | 1999-10-15 | Camel, an alternative translation product of the tumour antigen lage-1 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98119583A EP1001022A1 (en) | 1998-10-16 | 1998-10-16 | CAMEL, an alternative translation product of the tumour antigen LAGE-1 |
EP98119583 | 1998-10-16 | ||
EP99953854A EP1121435A1 (en) | 1998-10-16 | 1999-10-15 | Camel, an alternative translation product of the tumour antigen lage-1 |
PCT/EP1999/007832 WO2000023584A1 (en) | 1998-10-16 | 1999-10-15 | Camel, an alternative translation product of the tumour antigen lage-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1121435A1 true EP1121435A1 (en) | 2001-08-08 |
Family
ID=8232812
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98119583A Withdrawn EP1001022A1 (en) | 1998-10-16 | 1998-10-16 | CAMEL, an alternative translation product of the tumour antigen LAGE-1 |
EP99953854A Withdrawn EP1121435A1 (en) | 1998-10-16 | 1999-10-15 | Camel, an alternative translation product of the tumour antigen lage-1 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98119583A Withdrawn EP1001022A1 (en) | 1998-10-16 | 1998-10-16 | CAMEL, an alternative translation product of the tumour antigen LAGE-1 |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP1001022A1 (en) |
JP (1) | JP2002527109A (en) |
CA (1) | CA2346942A1 (en) |
MX (1) | MXPA01003697A (en) |
WO (1) | WO2000023584A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6794131B1 (en) | 1998-01-27 | 2004-09-21 | Ludwig Institute For Cancer Research | Lage-1 tumor associated nucleic acids |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004111075A2 (en) | 2003-03-05 | 2004-12-23 | Dendreon Corporation | Alternative reading frame polypeptides for treatment |
DE102018107224A1 (en) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptides and combinations of peptides of non-canonical origin for use in immunotherapy against various cancers |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE402259T1 (en) * | 1997-01-27 | 2008-08-15 | Ludwig Inst Cancer Res | LOCATION-1 TUMOR-ASSOCIATED NUCLEIC ACIDS |
EP1021535B1 (en) * | 1997-10-08 | 2007-03-07 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Human cancer antigen ny eso-1/cag-3 and gene encoding same |
-
1998
- 1998-10-16 EP EP98119583A patent/EP1001022A1/en not_active Withdrawn
-
1999
- 1999-10-15 EP EP99953854A patent/EP1121435A1/en not_active Withdrawn
- 1999-10-15 WO PCT/EP1999/007832 patent/WO2000023584A1/en not_active Application Discontinuation
- 1999-10-15 MX MXPA01003697A patent/MXPA01003697A/en unknown
- 1999-10-15 CA CA002346942A patent/CA2346942A1/en not_active Abandoned
- 1999-10-15 JP JP2000577294A patent/JP2002527109A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO0023584A1 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563870B2 (en) | 1997-01-27 | 2009-07-21 | Ludwig Institute For Cancer Research Ltd. | LAGE-1 tumor associated nucleic acids |
US7998483B2 (en) | 1997-01-27 | 2011-08-16 | Ludwig Institute For Cancer Research Ltd. | Lage-1 tumor associated nucleic acids |
US6794131B1 (en) | 1998-01-27 | 2004-09-21 | Ludwig Institute For Cancer Research | Lage-1 tumor associated nucleic acids |
Also Published As
Publication number | Publication date |
---|---|
CA2346942A1 (en) | 2000-04-27 |
WO2000023584A1 (en) | 2000-04-27 |
JP2002527109A (en) | 2002-08-27 |
EP1001022A1 (en) | 2000-05-17 |
MXPA01003697A (en) | 2003-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Aarnoudse et al. | Interleukin‐2‐induced, melanoma‐specific T cells recognize CAMEL, an unexpected translation product of LAGE‐1 | |
AU749544B2 (en) | Tumor antigen peptides originating in cyclophilin B | |
US20080107668A1 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
WO2007150077A2 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
CN113045636A (en) | Cancer antigen helper peptide | |
CA2722364A1 (en) | Melanoma antigens | |
WO2005095598A1 (en) | Cancer antigen peptide originating in wt1 | |
JP2012180359A (en) | Oligopeptide related to mhc class i related to melanoma, and use of the same | |
CA2772551A1 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
WO2009036246A2 (en) | Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer | |
AU748250B2 (en) | Tumor antigen peptide derivatives | |
CA2400842A1 (en) | Novel compounds | |
WO1997011669A2 (en) | Mhc-class ii restricted melanoma antigens and their use in therapeutic methods | |
US7071294B1 (en) | Tumor antigen protein art-1 and tumor antigen peptide thereof | |
AU756398B2 (en) | Novel compounds | |
EP1001022A1 (en) | CAMEL, an alternative translation product of the tumour antigen LAGE-1 | |
US6664232B1 (en) | HLA-A2 restraint tumor antigen peptide originating in SART-1 | |
MXPA01012012A (en) | Tumor-associated antigen (c42). | |
CA2441225C (en) | A novel trp2 isoform containing hla-a2 restricted cytotoxic t lymphocyte epitopes | |
AU2001275490A1 (en) | MHC peptides over-expressed on prostate cancer cells and methods of use | |
Kast | Peptide-based cancer vaccines | |
CA2387043A1 (en) | Colon-tumour-associated antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010516 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20040408 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20041019 |